Brainscan

BrainScan operates at the intersection of AI medical imaging, radiology workflow software, and regulated medical devices. Its core differentiation is not simply automated image classification: the company describes a decision-support system designed to reduce under-reporting and prioritize patients, with alerts for suspected intracranial bleeding and detection of multiple brain pathologies. The product is positioned for hospitals and emergency departments, where triage speed and integration with existing imaging workflows are central purchasing considerations. Its reported CE MDR Class IIa certification in 2023 provides a regulatory foundation for European commercialization, while on-premise deployment may appeal to hospitals that prefer tighter control over sensitive imaging data. The competitive field includes established imaging-AI vendors such as Aidoc, Viz.ai, and RapidAI, although BrainScan’s disclosed profile is more geographically focused and provides less evidence of scale, hospital coverage, or capital resources than those larger platforms. BrainScan’s main strategic challenge is likely converting regulatory validation and technical capability into repeatable international distribution and measurable clinical adoption.

BrainScan’s trajectory shows a progression from early grants and product development toward regulated commercialization. The company was founded in 2017, raised a $250,000 pre-seed round in August 2018, received an approximately $848,586 grant in April 2018, and added a $250,000 seed investment led by LSI (Life Science Innovations Fund) in April 2019. A further grant of approximately $1.13 million in January 2020 supported development, while a clinical evaluation proof of concept was introduced in October 2020. The company then raised approximately $495,509 in January 2022 and $1.43 million in a Series A on Jun 1, 2023. Product maturity is reflected in CE marking from 2019 and CE MDR Class IIa certification obtained in 2023. BrainScan reports a tagged brain CT database covering 250,000 examinations and a system capable of detecting up to 26 lesions, while website materials reference 30 pathologies. The employee range remains 11–50, with eight current positions listed.